Sanofi's antibody riliprubart has received orphan drug designation (ODD) from Japan's Ministry of Health, Labour and Welfare ...

Paris: Sanofi has received orphan drug designation from the Ministry of Health, Labour and Welfare (MHLW) in Japan for ...

The companies place the partnership’s value at up to $1.5 billion, including an undisclosed up-front payment in the ...

Riliprubart granted orphan drug designation in Japan for chronic inflammatory demyelinating polyneuropathy Two phase 3 studies are currently underway testing riliprubart in people with CIDP as a ...

(NASDAQ:ARGX) is down ~7% in Monday trading after the U.S. FDA issued an alert on a potential signal of serious risks associated with Vyvgart Hytrulo (efgartigimod alfa and hyaluronidase). The agency ...

One step at a time, those who are diagnosed with rare neuropathic conditions such as GBS or CIDP prove it's possible to get ...

Explore the latest on VYVGART HYTRULO's FDA safety signal and transition challenges. Learn why argenx's balanced risks keep ...

Japanese MHLW grants orphan drug designation to Sanofi’s riliprubart for chronic inflammatory demyelinating polyneuropathy: Paris Tuesday, July 1, 2025, 09:00 Hrs [IST] The Mini ...

Macrocyclic peptides are designed to engage complex targets like biologics but pass through cell membranes like small ...

Results of two phase 2 studies suggest efgartigimod could be a potential treatment for myositis and Sjögren disease in ...

Sanofi (ENXTPA:SAN) recently received orphan drug designation from Japan's Ministry of Health for riliprubart, aimed at treating chronic inflammatory demyelinating polyneuropathy. This underscores the ...

Riliprubart granted orphan drug designation in Japan for chronic inflammatory demyelinating polyneuropathy . Two phase 3 studies are currently underway testing riliprubart in people with CIDP as a ...